Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-CE19-004, Etiologic and Effectiveness Research To Address Polysubstance Impaired Driving; Amended Notice of Meeting
| Published date | 01 April 2019 |
| Citation | 84 FR 12256 |
| Record Number | 2019-06146 |
| Section | Notices |
| Court | Centers For Disease Control And Prevention |
12256
Federal Register / Vol. 84, No. 62 / Monday, April 1, 2019 / Notices
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Gopal Khanna,
Director.
[FR Doc. 2019–06192 Filed 3–29–19; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—CE19–004,
Etiologic and Effectiveness Research
To Address Polysubstance Impaired
Driving; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)–CE19–
004, Etiologic and Effectiveness
Research to Address Polysubstance
Impaired Driving; May 7–8, 2019; 8:30
a.m.–5:30 p.m., (EDT) which was
published in the Federal Register on
February 15, 2019, Volume 84, Number
32, page/s/4446–4447.
The meeting is being amended to
change the meeting location to The W
Buckhead, 3377 Peachtree Road, NE,
Atlanta, GA 30326]. The meeting is
closed to the public.
FOR FURTHER INFORMATION CONTACT
:
Mikel L. Walters, M.A., Ph.D., Scientific
Review Official, NCIPC, CDC, 4770
Buford Highway NE, Mailstop F–63,
Atlanta, Georgia 30341,(404) 639–0913;
mwalters@cdc.gov.
The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–06146 Filed 3–29–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1725–N]
Medicare Program; Meeting
Announcement for the Medicare
Advisory Panel on Clinical Diagnostic
Laboratory Tests
AGENCY
: Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION
: Notice.
SUMMARY
: This notice announces the
next public meeting dates for the
Medicare Advisory Panel on Clinical
Diagnostic Laboratory Tests (the Panel)
on Monday, July 22, 2019 and Tuesday,
July 23, 2019. The purpose of the Panel
is to advise the Secretary of the
Department of Health and Human
Services and the Administrator of the
Centers for Medicare & Medicaid
Services on issues related to clinical
diagnostic laboratory tests.
DATES
: Meeting Dates: The meeting of
the Panel is scheduled for Monday, July
22, 2019 from 8:00 a.m. to 4:30 p.m.,
Eastern Daylight Time (E.D.T.) and
Tuesday, July 23, 2019, from 8:00 a.m.
to 4:30 p.m., E.D.T. The Panel is also
expected to participate in the Clinical
Laboratory Fee Schedule (CLFS) Annual
Public Meeting for Calendar Year (CY)
2020 on June 24, 2019 in order to gather
information and ask questions to
presenters. Notice of the CLFS Annual
Public Meeting for CY 2020 is published
elsewhere in this issue of the Federal
Register.
Deadline for Registration: The public
may attend the Panel meeting in person,
view via webcast or listen via
teleconference. Beginning Monday,
April 8, 2019 and ending Monday, July
1, 2019 at 5:00 p.m. E.D.T., registration
to attend the Panel meeting in person
may be completed online at http://
cms.gov/Regulations-and-Guidance/
Guidance/FACA/AdvisoryPanelon
ClinicalDiagnosticLaboratoryTests.html.
On this web page, under ‘‘Panel
Meetings,’’ click the ‘‘Register for July
22 through 23, 2019 Panel Meeting’’ link
and enter the required information. We
refer readers to Section IV. of this notice
for additional details related to meeting
registration.
Webinar, Webcast, and
Teleconference Information:
Teleconference dial-in instructions, and
related webcast and webinar details will
be posted on the meeting agenda, which
will be available on the CMS website
approximately 2 weeks prior to the
meeting at https://www.cms.gov/
Regulations-and-Guidance/Guidance/
FACA/AdvisoryPanelonClinical
DiagnosticLaboratoryTests.html. A
preliminary agenda is described in
Section II. of this notice.
ADDRESSES
: The Panel meeting will be
held in the auditorium of the Centers for
Medicare & Medicaid Services (CMS),
Central Building, 7500 Security
Boulevard, Baltimore, Maryland 21244–
1850.
FOR FURTHER INFORMATION CONTACT
:
Rasheeda Arthur, Ph.D., (410) 786–3434,
email CDLTPanel@cms.hhs.gov. Press
inquiries are handled through the CMS
Press Office at (202) 690–6145. For
additional information on the Panel,
refer to the CMS website at https://
www.cms.gov/Regulations-and-
Guidance/Guidance/FACA/Advisory
PanelonClinicalDiagnosticLaboratory
Tests.html.
SUPPLEMENTARY INFORMATION
:
I. Background
The Medicare Advisory Panel on
Clinical Diagnostic Laboratory Tests (the
Panel) is authorized by section
1834A(f)(1) of the Social Security Act
(the Act) (42 U.S.C. 1395m–1), as
established by section 216(a) of the
Protecting Access to Medicare Act of
2014 (PAMA) (Pub. L. 113–93), enacted
on April 1, 2014. The Panel is subject
to the Federal Advisory Committee Act
(FACA), as amended (5 U.S.C.
Appendix 2), which sets forth standards
for the formation and use of advisory
panels.
Section 1834A(f)(1) of the Act directs
the Secretary of the Department of
Health and Human Services (the
Secretary) to consult with an expert
outside advisory panel established by
the Secretary, composed of an
appropriate selection of individuals
with expertise in issues related to
clinical diagnostic laboratory tests,
which may include the development,
validation, performance, and
application of such tests. Such
individuals may include molecular
pathologists, researchers, and
individuals with expertise in laboratory
science or health economics.
The Panel will provide input and
recommendations to the Secretary and
the Administrator of the Centers for
Medicare & Medicaid Services (CMS) on
the following:
•The establishment of payment rates
under section 1834A of the Act for new
clinical diagnostic laboratory tests,
including whether to use
‘‘crosswalking’’ or ‘‘gapfilling’’
processes to determine payment for a
specific new test.
VerDate Sep<11>2014 17:22 Mar 29, 2019 Jkt 247001 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 E:\FR\FM\01APN1.SGM 01APN1
